Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Suppression of plasmacytoid dendritic cell migration by compounds derived from natural medicines

ABSTRACT: Suppression of plasmacytoid dendritic cell migration by compounds derived from natural medicines

PROVIDER: PRJNA704551 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Suppression of plasmacytoid dendritic cell migration by compounds derived from natural medicines

Project description:Background and Aims. Dendritic cells (DCs) play a pivotal role in maintaining immunological homeostasis by orchestrating innate and adaptive immune responses via migration to inflamed sites and the lymph nodes (LNs). Plasmacytoid DCs (pDCs) have been reported to accumulate in the colon of inflammatory bowel disease (IBD) patients and dextran sulfate sodium (DSS)-induced colitis mice. However, the role of pDCs in the progression of colonic inflammation remains unclear. Methods. 80 compounds in natural medicines were searched for inhibitors of pDC migration using bone marrow-derived pDCs (BMpDCs) and conventional DCs (BMcDCs). BALB/c mice were given 3% DSS in the drinking water for 7 days to induce acute colitis. Compounds, which specifically inhibited pDC migration, were administrated into DSS-induced colitis mice. Results. Astragaloside IV (As-IV) and oxymatrine (Oxy) suppressed BMpDC migration but not BMcDC migration. In DSS-induced colitis mice, the number of pDCs was markedly increased in the colonic lamina propria (LP), and the expression of CCL21 was obviously observed in colonic isolated lymphoid follicles (ILFs). As-IV and Oxy reduced symptoms of colitis and the accumulation of pDCs in colonic ILFs but not in the colonic LP. Moreover, in a BMpDC adoptive transfer model, BMpDC migration to colonic ILFs was significantly decreased by treatment with As-IV or Oxy. Conclusion. pDCs accumulated in the colon of DSS-induced colitis mice, and As-IV and Oxy ameliorated DSS-induced colitis by suppressing pDC migration to colonic ILFs. Accordingly, the selective inhibition of pDC migration may be a potential therapeutic approach for treating colonic inflammatory diseases.

2021-07-06 | GSE167388 | GEO

Machine learning-based noninvasive assays explore the use of volatile organic compounds for clinical diagnosis and evaluation of gastrointestinal tumors

Project description:Interventions: Gold Standard:pathological diagnosis ;Index test:Volatile organic compounds detected by gas chromatography-mass spectrometer and gas chromatography-ion migration spectrometry Primary outcome(s): Volatile organic compounds;sensitivity;specificity Study Design: Diagnostic test for accuracy

| 89221 | ecrin-mdr-crc

DNA metabarcoding of traditional medicines

Project description:The application of multi-locus DNA metabarcoding in traditional medicines

| PRJEB25620 | ENA

Accelerating Medicines Partnership-Rheumatoid Arthritis (AMP-RA)

Project description:Accelerating Medicines Partnership-Rheumatoid Arthritis (AMP-RA)

| PRJNA407593 | ENA

Drug-likeness analysis of traditional Chinese medicines: 1. property distributions of drug-like compounds, non-drug-like compounds and natural compounds from traditional Chinese medicines.

Project description: Not available

| S-EPMC3538521 | biostudies-literature

Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm

Project description:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy originating from plasmacytoid dendritic cells (pDCs). The microRNA expression profile of BPDCN was compared to that of normal pDCs and the impact of miRNA dysregulation on the BPDCN transcriptional program was assessed. MiRNA and gene expression pro-filing data were integrated to obtain the BPDCN miRNA-regulatory network. The biological process mainly dysregulated by this network was predicted to be neurogenesis, a phenomenon raising growing interest in solid tumors. Neurogenesis was explored in BPDCN by querying different molecular sources (RNA sequencing, Chromatin immunoprecipitation-sequencing, and immunohistochemistry). It was shown that BPDCN cells upregulated neural mitogen genes possibly critical for tumor dissemination, expressed neuronal progenitor markers involved in cell migration, exchanged acetylcholine neurotransmitter, and overexpressed multiple neural re-ceptors that may stimulate tumor proliferation, migration and cross-talk with the nervous system. Most neural genes upregulated in BPDCN are currently investigated as therapeutic targets.

2021-09-17 | GSE184293 | GEO

Drug-likeness analysis of traditional Chinese medicines: 2. Characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional Chinese medicines.

Project description: Not available

| S-EPMC3561156 | biostudies-literature

Accelerating Medicines Partnership-Systemic Lupus Erythematosus (AMP-SLE)

Project description:Accelerating Medicines Partnership-Systemic Lupus Erythematosus (AMP-SLE)

| PRJNA407645 | ENA

Transcription profiling of human plasmacytoid dendritic cells treated with p17 or CpG

Project description:We used microarrays to detail the global program of gene expression underlying the effect of p17 on human plasmacytoid dendritic cells and was compared to CpG profile. Experiment Overall Design: Human plasmacytoid dendritic cells were purified from two donors and cultured in the presence of p17 or CpG for 18 h.

2008-04-07 | E-GEOD-10147 | biostudies-arrayexpress

Methylation data profiling for blastic plasmacytoid dendritic cell neoplasm

Project description:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive malignancy assumed to originate from plasmacytoid dendritic cells (pDCs), which affects the skin and bone marrow and sequentially other organ systems. Here, we used EPIC arrays to characterize methylation profiles in 51 BPDCN cases.

2024-02-11 | GSE230487 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data